Every 8-K that IGC Pharma, Inc. (IGC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IGC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IGC filings page.
IGC Pharma, Inc. is furnishing an updated investor presentation that focuses on IGC-AD1, an investigational oral liquid therapy in development for agitation in Alzheimer’s disease and related neuropsychiatric symptoms. The materials describe the multicenter CALMA Phase 2 trial for agitation in Alzheimer’s dementia, which has a target enrollment of 146 participants, with more than 80% reported as having completed dosing, and identify upcoming catalysts such as completion of enrollment and a topline readout.
The presentation highlights Phase 1 results in which IGC-AD1 was associated with improvements in Neuropsychiatric Symptoms measured by the NPI-12 scale, including a Cohort 1 total average score change from 31.5 at baseline to 14.8 at Day 15, a 53.02% reduction (p=0.005). It also provides blinded pooled CALMA Phase 2 CMAI agitation data that cannot establish treatment effect or efficacy, market context showing widespread agitation in Alzheimer’s, and a portfolio of multiple patent families. The company emphasizes that IGC-AD1 remains investigational and unapproved, that interim and blinded data are preliminary and may not predict final results, and that all valuation and market scenarios are illustrative and hypothetical.
IGC Pharma, Inc. entered into stock purchase agreements with its CEO Ram Mukunda and PFO Claudia Grimaldi, converting company payables into equity. The executives bought common stock at $0.27 per share, paid for by cancelling amounts the company owed them, including prior personal cash advances.
The company issued 2,226,475 shares to Mr. Mukunda in exchange for $601,148 of obligations and 2,048,378 shares to Ms. Grimaldi for $553,062. In total, $1,154,210 of outstanding obligations were eliminated with a corresponding increase in stockholders’ equity, and no cash left the company. The transactions were approved by independent directors and relied on a private-offering exemption under securities laws, with the new shares issued as restricted securities.
IGC Pharma, Inc. entered into an amendment with O-Bank Co., Ltd. on June 5, 2026, to extend its existing Master Loan and Security Agreement and General Banking Facility Letter. The banking facility continues to provide a maximum aggregate limit of $12,000,000 for the company.
Key terms remain substantially unchanged from the June 24, 2025 facility letter, except the facility fee has increased from $48,000 to $60,000. The agreement is characterized as a material definitive agreement and also creates a direct financial obligation for IGC under Item 2.03.
IGC Pharma entered into two securities purchase agreements, issuing promissory notes to FirstFire Global Opportunities Fund and Vanquish Funding Group to raise cash for general working capital. The FirstFire note has a principal of $346,910 (including original issue discount) and matures on April 10, 2027, while the VFG note has a principal of $238,050 and matures on March 30, 2027.
Both notes carry a 12% interest rate and may be prepaid in full with notice. If an Event of Default occurs and continues, each holder may convert amounts outstanding into common stock at a price equal to 75% of the lowest trading price over the prior ten trading days, subject to a 4.99% beneficial ownership limit and an overall 19.99% Conversion Cap unless shareholders approve more under NYSE American rules.
IGC Pharma, Inc. entered into a strategic 12-part national media partnership with FMW Media Works’ New to The Street platform to support its investor relations and corporate communications. The campaign will use long-form TV interviews, commercials, digital channels, and outdoor placements in major U.S. financial markets.
IGC will appear on sponsored programming on Fox Business and Bloomberg Television, with additional reach through more than 4.45 million YouTube subscribers, Times Square and New York City Financial District billboards, and curated events aimed at accredited investors. The company frames this effort as enhancing investor awareness while it advances its clinical-stage Alzheimer’s and metabolic disorder pipeline.
IGC Pharma, Inc. entered into new financing arrangements, including a promissory note with Vanquish Funding Group Inc. for a total principal of $353,050, reflecting an original issue discount of $46,050 on a cash purchase price of $307,000. The note matures on February 28, 2027 and can be prepaid at any time with notice. If an event of default occurs and continues, Vanquish may convert the outstanding balance into common shares at 75% of the lowest trading price over the prior 10 trading days, subject to a 4.99% beneficial ownership cap and a 19.99% conversion cap absent shareholder approval. IGC also obtained approximately $219,000 in additional financing through a loan agreement with One Deck Capital, Inc. Both financings are intended for general working capital and other corporate purposes.
IGC Pharma, Inc. entered into a Subscription Agreement for a registered direct offering of 779,997 shares of common stock at $0.30 per share, for gross proceeds of approximately $234 thousand before expenses. The offering is being made under an effective Form S-3 shelf registration statement and a related prospectus supplement dated January 5, 2026. Closing is expected to occur on or about January 5, 2026, subject to customary closing conditions. IGC plans to use the net proceeds for working capital and general corporate purposes, including funding clinical development programs, research and development activities, and other business initiatives.
IGC Pharma, Inc. is changing its fiscal year-end from March 31 to December 31, with the change effective on December 31, 2025. This adjustment aligns the company’s financial reporting with the standard calendar year, which can make its results easier to compare with many other public companies. To bridge the gap between the old and new year-end, IGC plans to file a transition annual report covering a nine-month period from April 1, 2025 through December 31, 2025, giving investors a complete view of operations during the changeover period.
IGC Pharma, Inc. reported a charter amendment that significantly expands its capacity to issue common shares. Effective December 12, 2025, the company increased its authorized common stock from 150,000,000 to 600,000,000 shares, following approval by stockholders at the Annual Stockholders Meeting held on October 10, 2025. Total authorized shares of all classes rose from 150,000,000 to 601,000,000, including 1,000,000 shares of preferred stock that were unchanged.
The aggregate par value of all par value shares increased from $15,100.00 to $60,100.00, reflecting the larger number of authorized shares. The amendment was filed with and accepted by the Maryland State Department of Assessments and Taxation, and a copy of the Articles of Amendment is included as an exhibit to this report.
IGC Pharma completed the previously announced sale of certain equipment, inventory, and operating assets from its Holi Hemp LLC Vancouver, Washington facility. The transactions under the Sale of Assets and Manufacturing Agreement with Wellness Essentials Northwest LLC were consummated on November 13, 2025 for a fair value of approximately $2.7 million, following satisfaction of closing conditions.
The company filed unaudited pro forma condensed consolidated financial statements reflecting this disposition, including a balance sheet as of June 30, 2025 and a statement of operations for the three months ended June 30, 2025. The agreement is available as an exhibit, providing detailed terms of the asset sale and manufacturing arrangements.
IGC Pharma (IGC) reported results from its 2025 Annual Meeting held on October 10, 2025. Stockholders elected Ram Mukunda and James Moran as Class C directors to serve until the 2028 annual meeting and ratified Manohar Chowdhry & Associates as the independent auditor for the 2026 fiscal year.
Shareholders approved the grant of 5,000,000 shares of common stock to be issued from time to time to employees, advisors, directors, and consultants based on board- or CEO-set performance, vesting, and incentive metrics. They also approved an amendment to increase authorized common stock from 150,000,000 to 600,000,000 shares. A non-binding advisory vote set the frequency of say-on-pay votes at every three years.
Participation was strong, with 53,776,307 shares voted, representing approximately 59.22% of the 90,809,112 shares outstanding and entitled to vote. Broker non-votes totaled 18,341,638.
IGC Pharma, Inc. reported that its wholly owned subsidiary Holi Hemp LLC, doing business as HH Processors, entered into a Sale of Assets and Manufacturing Agreement with Wellness Essentials Northwest Inc. The Buyer will acquire equipment, inventory, and a ready-to-move facility and assume employee, utility, lease, and other operating obligations.
The parties agreed on a fair value of approximately $2.7 million, subject to an auditor’s valuation review. Holi Hemp will receive preferential supply rights, and if the Buyer disposes of the operating business within five years, Holi Hemp is entitled to 10% of the net proceeds from that sale, all subject to customary closing conditions and internal approvals.